- Home
- SPFI vs VOR Comparison
SPFI vs VOR Comparison
Compare SPFI & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | VOR |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 1.1B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPFI | VOR |
|---|---|---|
| Price | $44.42 | $19.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $46.00 | $45.33 |
| AVG Volume (30 Days) | 150.0K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $52.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $1.62 |
| 52 Week High | $46.94 | $49.95 |
Technical Indicators
Market Signals| Indicator | SPFI | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 58.76 | 60.61 |
| Support Level | $39.06 | $11.62 |
| Resistance Level | $46.94 | $22.22 |
| Average True Range (ATR) | 1.34 | 1.48 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 58.19 | 77.34 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.